Necrotizing pneumonia (NP) is characterized by destruction of pulmonary tissue, resulting in multiple thin-walled cavities. There are limited reports on NP and parapneumonic effusion cases in children associated with Pseudomonas aeruginosa. Currently, there is no consensus regarding the optimal timing for video-assisted thoracoscopic surgery (VATS) following failure of chest tube placement and antibiotic treatment. A healthy 20-month-old child was hospitalized with symptoms of community-acquired pneumonia, progressing to severe NP and parapneumonic effusion. Despite receiving broad-spectrum antibiotics and chest tube placement on the third day of treatment, the condition continued to deteriorate, prompting VATS intervention on the sixth day. The presence of a “split pleural sign“ and extensive lung necrosis on chest computed tomography contributed to initial treatment failure. Multidrug resistance P. aeruginosa was identified through nasal trachea aspiration specimens on the eighth day of treatment, leading to an adjustment in antibiotic therapy to high-dose meropenem and amikacin. Subsequently, the patient became afebrile, showed clinical improvement, and was discharged after 35 days of treatment. Through this case, we aim to emphasize an unusual pathogenic bacteria in the context of NP and the need for standardized surgical interventions in pediatric patients with NP.
1 January 2024 in The Tohoku Journal of Experimental Medicine
Background: FIBTEM, a rotational thromboelastometry (ROTEM) component, assesses fibrin-based clot firmness and indirectly measures fibrinogen function. It offers faster turnaround time compared to the Clauss method for fibrinogen quantification, which may support early coagulation assessment in critically ill patients with sepsis. Objectives: Our study aims to evaluate the correlation between FIBTEM parameters and fibrinogen levels and predict the possibility of hyperfibrinogenemia using FIBTEM parameters in patients with sepsis. Design: A retrospective secondary analysis of a prospective observational study. Methods: Patients diagnosed with sepsis were recruited and admitted to the University Medical Center Ho Chi Minh City intensive care unit from June 2020 to December 2021. The international normalized ratio, activated partial thromboplastin time, platelet counts, fibrinogen levels, and FIBTEM parameters (A5, A10, A20, and maximum clot firmness (MCF)) were assessed for each patient. The correlations among laboratory parameters were assessed using the Pearson’s correlation coefficient. Predicted values of fibrinogen and FIBTEM were analyzed using simple linear regression, Bland–Altman plots, and Lin’s concordance correlation coefficient (CCC). The area under the receiver operating characteristic curve (AUC) and Kappa coefficients were calculated. Results: The median age of 159 patients with sepsis was 69. Males represented 51.6% of the participants. The percentage of patients with comorbidities was 88.1%. The mean plasma fibrinogen level was 5.4 ± 1.8 g/L. Fibrinogen levels were strongly correlated with FIBTEM parameters ( p < 0.01 for all values), including A5 ( r = 0.701), A10 ( r = 0.717), A20 ( r = 0.723), and MCF ( r = 0.735). MCF could not predict exact fibrinogen levels (CCC = 0.703). The AUC of the MCF to predict hyperfibrinogenemia was 0.905 (95% CI: 0.866–0.945), with a sensitivity of 85.5%, a specificity of 83.1%, and a Kappa coefficient of 0.69 at the optimal cut-off value of 22.5 mm. Conclusion: FIBTEM MCF could be a practical, rapid, surrogate tool for detecting hyperfibrinogenemia in sepsis and may help guide early clinical decisions before fibrinogen test results are available, although further validation in larger studies is required.
With the rise in vaping both in Vietnam and globally, acute complications related to vaping are becoming increasingly recognized. Although lung injury is t
26 February 2025 in Therapeutic Advances in Endocrinology and Metabolism
A hypercalcemic crisis (HC) is a life-threatening endocrine emergency if not promptly diagnosed and treated. Initial management for HC includes fluid resuscitation, diuresis, bisphosphonates, calcitonin, and glucocorticoids, along with diagnosing the underlying etiology of HC. However, for the refractory HC, continuous renal replacement therapy (CRRT) with regional citrate anticoagulation (RCA) should be considered. We report a case of severe refractory HC successfully managed with CRRT using RCA and surgery. A 56-year-old female patient was admitted to University Medical Center Ho Chi Minh City due to a decrease in consciousness. Laboratory tests and clinical manifestations suggested the diagnosis of primary hyperparathyroidism. The patient was managed with strategies to lower calcium levels, including intravenous normal saline, oral fluid replacement via nasogastric tube, calcitonin, and bisphosphonate; however, the patient did not respond to the initial treatment. Subsequently, the patient underwent CRRT with RCA and calcium-free replacement fluid to reduce the calcium level before parathyroidectomy. The patient was discharged after 10 days of hospitalization. CRRT with RCA appears to be a potential, effective, and safe method for treating refractory hypercalcemic crises. Further research is required to investigate the role of CRRT with RCA in refractory hypercalcemia.
There are limited case reports on individuals infected with Burkholderia cepacia who do not have typical risk factors, particularly pregnant women with beta-thalassemia. A 34-year-old pregnant female with beta-thalassemia trait and hypertension was admitted to the hospital. The patient was diagnosed with eclampsia and underwent a cesarean section. After two days following the surgery, the patient experienced hospitality-acquired pneumonia. B.cepacia was isolated from blood cultures, and antibiotic susceptibility testing indicated sensitivity to trimethoprim/sulfamethoxazole and levofloxacin. The patient responded to antibiotic treatment. These findings highlight the importance of prompt diagnosis and appropriate treatment in managing B.cepacia infections in pregnant beta-thalassemia patients.